Centocor Exiting Diagnostics Business To Focus Exclusively on Therapeutics
This article was originally published in The Gray Sheet
Executive SummaryCentocor's commitment to its core pharmaceutical operation has been reinforced by the company's Oct. 30 announcement that it will sell its oncology diagnostics business to the Japanese firm Fujirebio for $37.5 mil.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.